Table 4.

Correlation between PD-L1, VEGF, and SEMA4D expressions with clinicopathologic characteristics of EOC patients.

Variable	Cases (N)	SEMA4D expression (N)		P	VEGF expression (N)		P	PD-L1 expression (N)		P
		Negative	Positive		Negative	Positive		Negative	Positive
Age				0.463			0.466			0.150
≤52 years	62	27	35		39	23		36	26
>52 years	62	22	40		34	28		27	35
Menopausal status				0.457			0.852			0.362
Yes	76	28	48		44	32		36	40
No	48	21	27		29	19		27	21
Pathologic type				0.848			0.848			0.347
Serous carcinoma	82	33	49		49	33		39	43
Mucous and others	42	16	26		24	18		24	18
Histologic grade				0.001			0.060			0.027
G1−2	47	28	19		33	14		30	17
G3 or undifferentiated	77	21	56		40	37		33	44
FIGO Stage				0.093			<0.001			0.001
I–II	51	25	26		43	8		35	16
III–IV	73	24	49		30	43		28	45
LN metastasis				0.014			0.025			<0.001
No	76	37	39		51	25		50	26
Yes	48	12	36		22	26		13	35
Residual disease				0.010			0.835			0.148
<1 cm	93	43	50		54	39		51	42
≥1 cm	31	6	25		19	12		12	19
Ascites volume (mL)				0.628			0.007			0.016
<2,000	103	42	61		55	48		47	56
≥2,000	21	7	14		18	3		16	5
Serum CA125 (U/mL)				0.040			0.199			0.103
<573.35	74	35	39		40	34		33	41
≥573.35	50	14	36		33	17		30	20
Patients' response to BC				0.017			0.030			0.033
Response (CR, PR and SD)	63	18	45		31	19		26	37
Non-response (PD)	61	31	30		42	32		37	24

BC, bevacizumab plus single regimen chemotherapy; CR, Complete Response; PR, Partial Response; PD, Progressive Disease; SD, Stable Disease.